Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CRHBP | P24387 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044024 | 0.96 | HCAR3 (1.00) | HCAR3MAPTGAANPC1PKM | |
| SCHEMBL11242963 | 0.95 | HCAR3 (0.97) | HCAR3MAPTGAANPC1PKM | |
| SCHEMBL6044600 | 0.95 | HCAR3 (0.97) | HCAR3MAPTGAANPC1PKM | |
| SCHEMBL11208444 | 0.95 | HCAR3 (0.97) | HCAR3MAPTGAANPC1PKM | |
| SCHEMBL2688335 | 0.92 | HCAR3 (1.00) | HCAR3MAPTNPC1PKMALDH1A1 | |
| SCHEMBL11267808 | 0.89 | HCAR3 (0.81) | HCAR3MAPTGAANPC1PKM | |
| SCHEMBL3278681 | 0.88 | HCAR3 (0.78) | HCAR3MAPTALDH1A1PRSS1 | |
| SCHEMBL11238552 | 0.87 | HCAR3 (0.77) | HCAR3MAPTGAANPC1PKM | |
| SCHEMBL24032 | 0.86 | HCAR3 (1.00) | HCAR3MAPTALDH1A1KMT2A | |
| SCHEMBL28183325 | 0.86 | HCAR3 (0.86) | HCAR3MAPTGAANPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458102-B2 | Derivatives of tetracaine | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20140018422-A1 | DERIVATIVES OF TETRACAINE | WILLAMETTE UNIVERSITY (US) | 2014-01-16 | — | — | US | disclosed |
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| EP-0293978-B1 | (1H-AZOL-1-YLMETHYL)SUBSTITUTED BENZOTRIAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-09-15 | — | — | EP | disclosed |
| US-5039677-A | Estrogen inhibitor | JANSSEN PHARMACEUTICA N.V. (CA) | 1991-08-13 | — | — | US | disclosed |
| US-4943574-A | AROMATASE INHIBITORS, ESTROGEN DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-07-24 | — | — | US | disclosed |
| EP-0293978-A2 | (1H-azol-1-ylmethyl)substituted benzotriazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-12-07 | — | — | EP | disclosed |
| EP-0034836-B1 | PROCESS FOR PREPARING NITROAZO BENZENES | CIBA-GEIGY AG (CH) | 1983-07-13 | — | — | EP | disclosed |
| US-4347180-A | High caustic coupling process for preparing substituted 2-nitro-2'-hydroxyazobenzenes | CIBA-GEIGY CORPORATION (US) | 1982-08-31 | — | — | US | disclosed |
| US-4275004-A | High caustic coupling process for preparing substituted 2-nitro-2'-hydroxyazobenzenes | CIBA-GEIGY CORPORATION (US) | 1981-06-23 | — | — | US | disclosed |
| US-4230867-A | REDUCTION, CYCLIZATION OF NITROAZOBENZENES | CIBA-GEIGY CORPORATION (US) | 1980-10-28 | — | — | US | disclosed |
| US-4219480-A | REDUCTION OF UNDESIRED BY-PRODUCT AND EFFLUENT POLLUTION PROBLEMS | CIBA-GEIGY CORPORATION (US) | 1980-08-26 | — | — | US | disclosed |
| EP-0006564-A2 | 2-(3.5-disubstituted-2-hydroxyphenyl)-2H-benzotriazoles and stabilized compositions containing them | CIBA-GEIGY AG (CH) | 1980-01-09 | — | — | EP | disclosed |
| US-4141903-A | REDUCTION AND CYCLIZATION OF THE CORRESPONDING O-NITROAZOBENZENES WITH CARBON MONOXIDE USING A COPPER-AMINE COMPLEX AS CATALYST | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
| US-4041044-A | BY REDUCTION OF CORRESPONDING O-NITRO-AZOBENZENES WITH ZINC IN AQUEOUS ALKALI METAL HYDROXIDE | CIBA-GEIGY CORPORATION (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018422-A1 | DERIVATIVES OF TETRACAINE | CACNA1G, CACNA1H, CACNA1I | HCAR3 140/4885MAPT 1590/4885GAA 1848/4885 |
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | HCAR3 85/4885MAPT 3284/4885GAA 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.